{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:38:27Z","timestamp":1786747107960,"version":"build-2736575974"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijc.ijc_448_19","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T22:49:55Z","timestamp":1574981395000},"page":"10","source":"Crossref","is-referenced-by-count":10,"title":["Adverse effects of immuno-oncology drugs\u2014Awareness, diagnosis, and management: A literature review of immune-mediated adverse events"],"prefix":"10.4103","volume":"56","author":[{"given":"Shyam","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.272012-1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0019-509X.272012-2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0019-509X.272012-3","first-page":"375","article-title":"Cancer immunotherapy, Part 1: Current strategies and agents","author":"Ventola","year":"2017","journal-title":"P T"},{"key":"key-10.4103\/0019-509X.272012-4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","article-title":"Delivering safer immunotherapies for cancer","author":"Milling","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"key-10.4103\/0019-509X.272012-5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations","author":"Hoos","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/0019-509X.272012-6","first-page":"452","article-title":"Cancer immunotherapy, Part 2: Efficacy, safety, and other clinical considerations","author":"Ventola","year":"2017","journal-title":"P T"},{"key":"key-10.4103\/0019-509X.272012-7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.272012-8","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.272012-9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc3973","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","author":"Melero","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"key-10.4103\/0019-509X.272012-10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"Paradigm shift in cancer immunotherapy: From enhancement to normalization","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"key-10.4103\/0019-509X.272012-11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: Strategies for patient monitoring and management of immune-mediated adverse events","author":"Davies","year":"2017","journal-title":"Immunotargets Ther"},{"key":"key-10.4103\/0019-509X.272012-12","first-page":"1","article-title":"Clinical assessment of immune-related adverse events","author":"Sosa","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"key-10.4103\/0019-509X.272012-13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.272012-14","first-page":"1","article-title":"Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials","author":"Wei","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"key-10.4103\/0019-509X.272012-15","first-page":"1","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"key-10.4103\/0019-509X.272012-16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.272012-17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"key-10.4103\/0019-509X.272012-18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials","author":"El-Osta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"key-10.4103\/0019-509X.272012-19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Society for Immunotherapy of Cancer Toxicity Management Working Group.Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"key-10.4103\/0019-509X.272012-20","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"; ESMO Guidelines Committee.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.272012-21","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: A meta-analysis","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"key-10.4103\/0019-509X.272012-22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.272012-23","doi-asserted-by":"crossref","first-page":"e15065","DOI":"10.1200\/JCO.2018.36.15_suppl.e15065","article-title":"Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience","author":"Gupta","year":"2018","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.272012-24","doi-asserted-by":"crossref","first-page":"e16546","DOI":"10.1200\/JCO.2018.36.15_suppl.e16546","article-title":"Real world experience with nivolumab in Indian patients with metastatic renal cell carcinoma: A single centre experience","author":"Rauthan","year":"2018","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.272012-25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA- 4 antibodies: Systematic review and meta-analysis","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"key-10.4103\/0019-509X.272012-26","first-page":"56","article-title":"Incidence of immune-related adverse events with program death Receptor-1- and program death Receptor-1 ligand-directed therapies in genitourinary cancers","author":"Maughan","year":"2017","journal-title":"Front Oncol"},{"key":"key-10.4103\/0019-509X.272012-27","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1\/2 open-label study","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"key-10.4103\/0019-509X.272012-28","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"key-10.4103\/0019-509X.272012-29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0019-509X.272012-30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0019-509X.272012-31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.intimp.2018.08.014","article-title":"Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials","author":"Zhang","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"key-10.4103\/0019-509X.272012-32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.272012-33","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.272012-34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"key-10.4103\/0019-509X.272012-35","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"key-10.4103\/0019-509X.272012-36","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/TCRM.S143939","article-title":"Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: A systematic review and meta-analysis","author":"Cui","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"key-10.4103\/0019-509X.272012-37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"key-10.4103\/0019-509X.272012-38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.272012-39","doi-asserted-by":"crossref","first-page":"e1214788","DOI":"10.1080\/2162402X.2016.1214788","article-title":"Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma","author":"Liniker","year":"2016","journal-title":"Oncoimmunology"},{"key":"key-10.4103\/0019-509X.272012-40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijrobp.2017.01.063","article-title":"Tolerability and safety of thoracic radiation and immune checkpoint inhibitors among patients with lung cancer","author":"Ahmed","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"key-10.4103\/0019-509X.272012-41","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0019-509X.272012-42","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I\/II study","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.272012-43","first-page":"119","article-title":"Special topics in immunotherapy and radiation therapy: Reirradiation and palliation","author":"Evans","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"key-10.4103\/0019-509X.272012-44","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.272012-45","doi-asserted-by":"crossref","first-page":"e000200","DOI":"10.1136\/esmoopen-2017-000200","article-title":"Immune checkpoint inhibitors for advanced non-small cell lung cancer: Emerging sequencing for new treatment targets","author":"Aguiar","year":"2017","journal-title":"ESMO Open"},{"key":"key-10.4103\/0019-509X.272012-46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"key-10.4103\/0019-509X.272012-47","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/bjc.2016.107","article-title":"Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy","author":"Bowyer","year":"2016","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0019-509X.272012-48","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.272012-49","first-page":"408","article-title":"Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C","author":"Rai","year":"2017","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.272012-50","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jgo.2016.05.007","article-title":"The development of immunotherapy in older adults: New treatments, new toxicities?","author":"Helissey","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"key-10.4103\/0019-509X.272012-51","doi-asserted-by":"crossref","first-page":"10010","DOI":"10.1200\/JCO.2016.34.15_suppl.10010","article-title":"FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers","author":"Singh","year":"2016","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.272012-52","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1blockade in patients with non-small-cell lung cancer","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.272012-53","first-page":"42","article-title":"PD-1 inhibitor therapy: Consensus statement from the faculty of the melanoma nursing initiative on managing adverse events","author":"McGettigan","year":"2017","journal-title":"Clin J Oncol Nurs"},{"key":"key-10.4103\/0019-509X.272012-54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","author":"Mekki","year":"2018","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0019-509X.272012-55","first-page":"265","article-title":"The ION-Ghent guidelines for the management of immune related adverse events (irAE's)","author":"Kruse","year":"2017","journal-title":"Belgian J Med Oncol"},{"key":"key-10.4103\/0019-509X.272012-56","first-page":"1","article-title":"0","author":"National","year":"27,","journal-title":"Published: November"},{"key":"key-10.4103\/0019-509X.272012-57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"key-10.4103\/0019-509X.272012-58","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.272012-59","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.272012-60","doi-asserted-by":"crossref","unstructured":"Hamamoto Y, Shin N, Hoshino T, Kanai T. Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. Future Oncol 2018. doi: 10.2217\/fon-2018-0509. [Epub ahead of print].","DOI":"10.2217\/fon-2018-0509"},{"key":"key-10.4103\/0019-509X.272012-61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res"},{"key":"key-10.4103\/0019-509X.272012-62","first-page":"1","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","author":"Girotra","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"key-10.4103\/0019-509X.272012-63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): Pooled results from two expansion cohorts of an open-label, phase 1 trial","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0019-509X.272012-64","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.272012-65","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"key-10.4103\/0019-509X.272012-66","doi-asserted-by":"crossref","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: A preplanned interim analysis of a clinical trial","author":"D'Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"key-10.4103\/0019-509X.272012-67","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:41:00Z","timestamp":1786732860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_448_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"alternative-id":["272012"],"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_448_19","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}